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OBJECTIVES We studied the prognostic implications of midwall fibrosis in dilated cardiomyopathy (DCM)
in a prospective longitudinal study.
BACKGROUND Risk stratification of patients with nonischemic DCM in the era of device implantation is
problematic. Approximately 30% of patients with DCM have midwall fibrosis as detected by
late gadolinium-enhancement (LGE) cardiovascular magnetic resonance (CMR), which may
increase susceptibility to arrhythmia and progression of heart failure.
METHODS Consecutive DCM patients (n  101) with the presence or absence of midwall fibrosis were
followed up prospectively for 658  355 days for events.
RESULTS Midwall fibrosis was present in 35% of patients and was associated with a higher rate of the
predefined primary combined end point of all-cause death and hospitalization for a
cardiovascular event (hazard ratio 3.4, p  0.01). Multivariate analysis showed midwall
fibrosis as the sole significant predictor of death or hospitalization. However, there was no
significant difference in all-cause mortality between the 2 groups. Midwall fibrosis also
predicted secondary outcome measures of sudden cardiac death (SCD) or ventricular
tachycardia (VT) (hazard ratio 5.2, p  0.03). Midwall fibrosis remained predictive of
SCD/VT after correction for baseline differences in left ventricular ejection fraction between
the 2 groups.
CONCLUSIONS In DCM, midwall fibrosis determined by CMR is a predictor of the combined end point of
all-cause mortality and cardiovascular hospitalization, which is independent of ventricular
remodeling. In addition, midwall fibrosis by CMR predicts SCD/VT. This suggests a
potential role for CMR in the risk stratification of patients with DCM, which may have value
in determining the need for device therapy. (J Am Coll Cardiol 2006;48:1977–85) © 2006
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.07.049by the American College of Cardiology Foundation
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Nonischemic dilated cardiomyopathy (DCM)
is associated with significant morbidity and
premature mortality (1). Several trials have
shown the outcome benefits from device im-
plantation in this group of patients (2–5), but at
considerable cost (6) and risk of complica-
See page 1986
ions (7). In addition, a proportion of patients with cardiac
esynchronization therapy (CRT) do not seem to respond
8), whereas many patients with an implantable
ardioverter-defibrillator will not experience device activa-
ion (9). There is therefore a pressing need for improved
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ccepted July 12, 2006.dentification of those at risk of progressive deterioration
equiring hospitalization and sudden cardiac death (SCD).
In patients with ventricular dysfunction, an important
echanism for the occurrence of arrhythmias and failure to
espond to treatment is the presence of myocardial fibrosis
10–12). Although there is extensive evidence to implicate
he role of fibrosis after infarction, the significance of
brosis in DCM is unclear. Approximately 30% of patients
ith DCM have midwall fibrosis as determined by late
adolinium-enhancement (LGE) cardiovascular magnetic
esonance (CMR) (13). This midwall fibrosis is distinct
rom infarction in sparing the subendocardium. We have
peculated that fibrosis in DCM might predict outcome
13). We tested this hypothesis in a prospective study
omparing the clinical outcomes in DCM patients with or
ithout midwall fibrosis.
ETHODS
atient population. Patients with DCM (n  101) and
mpaired systolic function were prospectively recruited be-
ween June 2000 and December 2003 from consecutive
eferrals from centers in southeast England. The diagnosis
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Prognosis in DCM by CMR November 21, 2006:1977–85f DCM was made according to World Health Organiza-
ion/International Society and Federation of Cardiology
riteria (14). All patients had chronic heart failure of at least
2 months’ duration and had presented with symptoms and
nset typical of chronic heart failure, including slowly
rogressive breathlessness, fatigue, and palpitations. None
f the patients in this study had clinical symptoms or signs
f ongoing myocarditis. Significant coronary artery disease
CAD) (50% diameter luminal stenosis in any coronary
rtery) was excluded in 98 patients by coronary angiography.
wo patients declined coronary angiography but had nor-
al myocardial perfusion scans. One asymptomatic patient,
ge 18 with a strong family history of DCM, did not
ndergo either test. Any patients with clinical evidence of
eft ventricular (LV) damage caused by CAD were excluded.
hese included patients with a clinical history and typical
lectrocardiogram associated with biochemical, angio-
raphic, or CMR evidence of previous myocardial infarc-
ion. Patients with a normal CMR-derived ejection fraction
EF) were also excluded (EF 56%, n  21). These 21
xcluded patients had been referred for CMR with possible
entricular dysfunction based on echocardiography with
oor acoustic windows, but none showed evidence of
idwall fibrosis, none were on treatment for heart failure at
he time of referral, and none are currently receiving heart
ailure treatment. Other exclusion criteria were the presence
f any contraindications to CMR, significant valvular dis-
ase, hypertrophic cardiomyopathy, or any evidence of
nfiltrative heart disease. All participants gave written in-
ormed consent. The project was approved by our institu-
ional ethics committee.
MR. Cardiovascular magnetic resonance (Siemens So-
ata 1.5-T, Erlangen, Germany) was performed using
teady-state, free precession breath-hold cines (TE [echo
ime]/TR [repetition time] 1.6/3.2 ms, flip angle 60°) in
ong-axis planes and sequential 7-mm short-axis slices
3-mm gap) from the atrioventricular ring to the apex. The
GE images were acquired 10 min after intravenous
adolinium-DTPA (Schering, Berlin, Germany; 0.1 mmol/
g) in identical short-axis planes using an inversion-recovery
Abbreviations and Acronyms
CAD  coronary artery disease
CI  confidence interval
CMR  cardiovascular magnetic resonance
CRT  cardiac resynchronization therapy
DCM  dilated cardiomyopathy
EDV  end-diastolic volume
EF  ejection fraction
ESV  end-systolic volume
LGE  late gadolinium enhancement
LV  left ventricle/ventricular
RV  right ventricle/ventricular
SCD  sudden cardiac death
VT  ventricular tachycardiaradient echo sequence (13). Inversion times were adjusted (o null normal myocardium (typically 320 to 440 ms; pixel
ize 1.7 1.4 mm). In all patients, imaging was repeated for
ach short-axis image in 2 separate phase-encoding direc-
ions to exclude artifact. Midwall LGE was only deemed to
e present when the area of signal enhancement could be
een in both phase-swapped images and in a cross-cut
ong-axis image by the independent observers (Fig. 1). The
GE was assessed visually, and the volume was measured by
anual planimetry by 2 independent readers blinded to all
atient details. The planimetered areas had a signal intensity
f 2 SD above the mean intensity of remote myocardium
n the same slice (15). Patients were divided into those with
nhancement (LGE) and those without (LGE). Fibro-
is volume was expressed as a percentage of total myocardial
ass (%LGE). Ventricular volumes and function were
easured for both ventricles using standard techniques (16),
nd analyzed using semiautomated software (CMRtools,
ardiovascular Imaging Solutions, London, United
ingdom).
vent data. Patient events were recorded by communica-
ion with patients, their cardiologists, and general practitio-
ers. Medical records were reviewed after attendance at
utpatient clinics or hospitalization. All patients were di-
ectly contacted at enrollment and at 3-month to 6-month
ntervals during follow-up. If the general practitioner had
ot contacted the patient for 3 months, the patient was
irectly contacted. In one case, in which the patient could
ot be reached, a national death register showed that the
atient had died of heart failure. No patient was lost to
ollow-up. The prespecified primary end point was a com-
osite of all-cause mortality or hospitalization for a cardio-
ascular event (2,5). Secondary end points were the occur-
ence of SCD or sustained ventricular tachycardia (defined
s ventricular extrasystoles at 120 beats/min lasting for
30 s on an electrocardiogram or 24-h tape) and all-cause
ortality alone. Patient data were censored at the time of
ny transplantation. The cause of death was identified in all
ases. Death caused by heart failure was defined as death
receded by signs or symptoms of heart failure; SCD was
efined as death with or without documented ventricular
rrhythmia within 1 h of new symptoms, or nocturnal death
ith no antecedent history of worsening symptoms (17).
tatistical analysis. Continuous data are expressed as a mean
alues SD. The baseline characteristics of the 2 groups were
ompared with the independent sample t test for continuous
ariables, and chi-square or Fisher exact tests for categorical
ariables. Survival estimates and cumulative event rates were
ompared by the Kaplan-Meier method using the time to first
vent for each end point. The log-rank test was used to
ompare the Kaplan-Meier survival curves. The hazard ratio
as calculated using a Cox regression model with computed
5% confidence intervals (CI). Multivariate analysis was also
erformed using covariates known to affect the end points,
amely age, LV end-systolic volume (ESV), LV end diastolic
olume (EDV), LVEF, right ventricular ejection fraction
RVEF), and digoxin therapy. Linear regression and Bland-
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November 21, 2006:1977–85 Prognosis in DCM by CMRltman analysis were used to assess the correlation between the
independent observers performing LGE planimetry. Odds
atios and CIs were calculated using binary logistic regression
nalysis to investigate for the presence of any significant
ssociations between the primary end point (categorical data)
nd %LGE, LVEDV, LVESV, or LVEF (continuous data).
The duration of follow-up was computed using the date
f entry into the study (day of the CMR scan) to the date of
he first end point reached. For patients who did not reach
n end point, follow-up data were collected to the time of
heir last clinical follow-up. A p value of0.05 was deemed
ignificant, and SPSS for Windows (version 12.0, SPSS
nc., Chicago, Illinois) was used for all statistical analyses.
ESULTS
aseline characteristics. Group baseline characteristics are
ummarized in Table 1. The LGE patients were younger,
ith larger LV volumes and a lower LV EF. The RV
olumes were not significantly different, but LGE patients
ad a lower RV EF. Baseline medical treatment of the 2
roups was comparable, except that a higher proportion of
GE patients received digoxin. There was no difference
n the duration of heart failure before enrollment.
utopsy data. One patient with familial DCM who died
nderwent autopsy. Comparison of the macroscopic appear-
nce of the cut surface of the heart suggested midwall
brosis particularly affecting the inferior and lateral walls,
nd fibrosis was confirmed using Sirius-red staining. There
igure 1. Late gadolinium enhancement patterns in dilated cardiomyopath
ate enhancement is shown in A and B, and a patient with marked midwall e
rom that associated with coronary artery disease because of endocardial sas excellent agreement between the pathological location if the midwall fibrosis and the premortem location of the
idwall LGE (Fig. 2).
urvival analysis. Data were collected for a total of 182
atient-years of follow-up. The mean duration of follow-up
as 658  355 days. There were 10 deaths (6 LGE
atients [17%]; 4 LGE [6%] patients), resulting in an
nnual mortality rate of 5.4% per year. In the LGE group,
patients died of heart failure, 2 of SCD, and 1 of
rug-related acute hepatic failure. In the LGE group, 2
atients died of heart failure and 2 patients of SCD.
aplan-Meier analysis showed no significant difference in
ll-cause mortality between the 2 groups (p  0.10).
There were episodes of hospitalization for 13 patients.
one of the patients had been hospitalized in the 3 months
efore enrollment. Four patients each in the LGE group
11%) and LGE (6%) group were admitted for unplanned
reatment of decompensated heart failure with intravenous
iuretics. Three patients in the LGE group were admitted
ith sustained ventricular tachycardia (VT) requiring emer-
ency cardioversion (9%). Finally, 1 patient in each of the
GE (3%) and LGE (2%) groups was admitted with
yncope. Orthotopic cardiac transplantation was performed
n 3 patients (all LGE, 9%) for end-stage progressive
eart failure.
The LGE patients had a significantly higher incidence
f the primary end point (all-cause mortality or hospitaliza-
ion for cardiovascular causes [hazard ratio 3.4; 95% CI 1.4
o 8.7; p  0.01]) (Fig. 3A). Using a Cox regression model
vertical long axis (A and C) and short axis (B and D). A patient without
cement is shown in C and D. The enhancement pattern (arrows) is distinct
and noncoronary territory distribution.y inncluding presence of LGE, age, LVESV, LVEDV, LVEF,
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Prognosis in DCM by CMR November 21, 2006:1977–85VEF, and treatment with digoxin, the presence of LGE
as the sole significant predictor of outcome (hazard ratio
.1; 95% CI 1.1 to 8.5; p  0.03) (Fig. 3B). The difference
Table 1. Baseline Characteristics of the Two S
Characteristic LGE
Age (yrs) (SD)
Male (%)
Family history of DCM (%)
History of diabetes (%)
History of hypertension (%)
History of smoking (%)
History of alcohol excess (%)
Increased BMI (%)
Heart failure duration (months)
Systolic BP (mm Hg) 1
Diastolic BP (mm Hg)
Heart rate (beats/min)
NYHA functional class (%)
I
II
III
IV
Medication (%)
ACEi
AT II blocker
Beta-blocker
Spironolactone
Digoxin
Diuretics
Anticoagulation
Amiodarone
Statins
CMR dimensions and function (SD)
LV EDV (ml) 2
LV ESV (ml) 1
LV EF (%)
LV mass (g) 1
RV EDV (ml) 1
RV ESV (ml) 1
RV EF (%)
ACEi  angiotensin-converting enzyme inhibitor; AT II 
blood pressure; DCM  dilated cardiomyopathy; EDV  e
volume; LGE patients with late gadolinium enhancemen
left ventricular; NYHA  New York Heart Association; RV
igure 2. (A) Macroscopic short-axis section of the right and left ventricle
idwall fibrosis (straight arrows), mainly in the inferior and lateral walls, b
f the heart in which Sirius red staining confirms collagen (arrow) in area
he collagen (red). (C) Premortem cardiovascular magnetic resonance of the sam
reas of late gadolinium enhancement (matching arrows).etween the two groups was accentuated if elective admis-
ions for biventricular/right ventricular pacemakers were
ncluded (hazard ratio 3.6; 95% CI 1.6 to 7.8, p  0.001).
Groups
 66) LGE (n  35) p Value
3) 48 (14) 0.045
1) 23 (66) 0.57
4) 8 (23) 0.23
) 1 (3) 0.48
8) 2 (6) 0.084
) 2 (6) 1.0
5) 3 (9) 0.53
5) 2 (6) 0.20
0) 24 (24) 0.61
6) 115 (21) 0.19
) 72 (14) 0.39
4) 76 (14) 0.66
0) 3 (9) 0.10
4) 20 (57)
4) 11 (31)
) 1 (3)
7) 28 (80) 0.75
3) 8 (23) 0.24
7) 24 (69) 0.28
1) 13 (37) 0.085
1) 10 (29) 0.022
1) 21 (60) 0.068
4) 12 (34) 0.28
) 3 (9) 0.93
) 3 (9) 0.69
0) 284 (108) 0.020
7) 199 (96) 0.0082
2) 31 (12) 0.0064
6) 134 (63) 0.69
7) 177 (51) 0.46
6) 98 (42) 0.12
2) 41 (11) 0.044
tensin 2 receptor blocker; BMI  body mass index; BP 
stolic volume; EF  ejection fraction; ESV  end-systolic
 patients without late gadolinium enhancement; LV
ght ventricular.
midventricular level from a patient with dilated cardiomyopathy showing
o in the lower and upper septum (curved arrows). (B) Microscopic section
brosis seen macroscopically. Myocytes (stained yellow) are admixed withtudy
 (n
53 (1
47 (7
9 (1
4 (6
12 (1
5 (8
10 (1
10 (1
28 (4
20 (1
74 (9
74 (1
20 (3
29 (4
16 (2
1 (2
51 (7
9 (1
38 (5
14 (2
7 (1
27 (4
16 (2
6 (9
4 (6
35 (7
50 (6
38 (1
39 (6
85 (5
12 (4
48 (2
angio
nd-diaat a
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s of fie slice, with excellent accord between the areas of macroscopic fibrosis and
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November 21, 2006:1977–85 Prognosis in DCM by CMRFor the secondary end points, LGE patients had a higher
ncidence of SCD/VT (hazard ratio 5.2; 95% CI 1.0 to 26.9; p
0.03) (Fig. 4A). Because of the low event rates (seven events
n total), multivariate analysis was performed using only LVEF
ecause this is the most widely used clinical marker of arrhyth-
ic risk in patients with heart failure (5). The LGE remained
significant predictor of outcome when multivariate analysis
orrecting for LVEF was performed (hazard ratio 5.9; 95% CI
.1 to 32.2; p  0.04) (Fig. 4B).
orrelation between extent of LGE and outcome. Linear
egression analysis showed a high correlation between the 2
bservers for planimetry of %LGE (r  0.95, p  0.01).
he median %LGE in LGE patients was 4.6%, with a
ange of 0.8% to 21%. In addition, Bland-Altman analysis
igure 3. (A) Kaplan-Meier survival estimates for the primary end point
ata adjusted for baseline differences in age, left ventricular (LV) end-sys
jection fraction, and treatment with digoxin. LGE  patients with
nhancement.
igure 4. (A) Kaplan-Meier survival estimates for the secondary end poin
djusted for baseline differences in left ventricular ejection fraction. LGE  pa
adolinium enhancement.howed a mean difference in observations of 0.19% with a
tandard deviation of differences of 3.62%. Using binary
ogistic regression to derive the probability of having an
vent, the extent of late enhancement expressed as %LGE
as strongly associated with outcome and was found to be
he sole significant predictor of an event when compared
ith LVESV, LVEDV, and LVEF for the primary end
oint of death or hospitalization (odds ratio 1.12; 95% CI
.03 to 1.24; p  0.02) (Fig. 5A). In addition, when
onsidering just the 35 patients in the LGE group, a
eceiver-operating characteristic analysis showed the optimal
LGE, which predicts that outcome was 4.8%. When the
GE group was further subdivided into LGE  4.8% and
GE  4.8%, Kaplan-Meier analysis showed a strong trend
cause mortality or hospitalization due to cardiovascular causes. (B) Same
volume, LV end-diastolic volume, LV ejection fraction, right ventricular
gadolinium enhancement; LGE  patients without late gadolinium
sudden cardiac death or sustained ventricular tachycardia. (B) Same dataof all-
tolict of
tients with late gadolinium enhancement; LGE  patients without late
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Prognosis in DCM by CMR November 21, 2006:1977–85oward a significant difference in outcome between the two
roups for the primary end point of all-cause mortality and
ospitalization (Fig. 5B).
ISCUSSION
atients with DCM have increased mortality because of
rogressive heart failure and SCD (18). Accurate risk
tratification is important in identifying those patients who
ould benefit from costly and invasive procedures such as
evice implantation. In this prospective study, we investi-
ated the prognostic implications of midwall fibrosis
LGE) in a cohort of patients with confirmed nonisch-
mic DCM. The overall occurrence of LGE (35%) was
imilar to that found in previous studies (13). The data show
hat patients with fibrosis had a significantly worse outcome
f the primary end point, all-cause death or cardiac hospi-
alization. In addition, despite the relatively low number of
vents, patients with fibrosis had a significantly greater
ncidence of the secondary end point of SCD/VT. Impor-
antly, by multivariate analysis, the prognostic value of the
resence of fibrosis was independent of established markers
f adverse outcome, including age and LV and RV volume/
unction (19,20). There was a trend toward a higher rate of
ll-cause mortality in the patients with fibrosis, but the
tudy seems underpowered for this comparison.
Our results also suggest that %LGE has a role in
redicting outcome. The %LGE was associated with a
igher probability of the primary end point of death and
ospitalization. The association between %LGE and out-
igure 5. (A) Binary logistic regression analysis comparing the extent of
entricular end-diastolic volume (LVEDV), and left ventricular ejection f
ssociation between %LGE and outcome, and %LGE was the sole signific
.03 to 1.24, p  0.02). (B) Kaplan-Meier subgroup analysis of the 35 pat
GE). The analysis shows a trend (p  0.07) toward a significant differen
atients with late gadolinium enhancement; LGE  patients without laome was better than for established prognostic parameters such as LVESV, LVEDV, and LVEF. We believe that the
urrent study is the first to identify the prognostic signifi-
ance of in vivo detection of myocardial fibrosis in patients
ith DCM.
In the current era of device implantation, LVEF is a
ajor determinant of stratification to therapy, and yet it is
poor guide to outcome and treatment benefit. In DCM, a
igh proportion of patients show evidence of myocardial
brosis in addition to LV dilatation and global hypokinesis.
his has been shown in explanted hearts from transplanta-
ion and postmortem studies and, in this study, in the
utopsy case available. Both reactive (interstitial and
erivascular) and reparative (replacement) patterns of fibro-
is are seen in DCM (21,22). The fibrosis may reflect
nflammation as well as microvascular ischemia (23,24).
The mechanisms for midwall fibrosis are thought to be
he result of a combination of factors including genetic
redisposition, exposure to toxins and pathogens, microvas-
ular ischemia, and abnormal modulation of immune and
etabolic responses such as overactivity of the renin angio-
ensin aldosterone system (21,23,25–28). Case reports exist
f midwall fibrosis in familial conditions such as muscular
ystrophy (29). In the cohort of patients described in the
resent study, 8 patients with familial cardiomyopathy had
idwall fibrosis. The underlying pathological mechanisms
or this familial propensity to fibrosis may be explained by
he fact that a number of defective genes implicated in
amilial DCM have also been found to code for cytoskeletal
roteins (25), and this could set up a chronic injury–repair
hancement (%LGE), left ventricular end-systolic volume (LVESV), left
n (LVEF) as predictors of death or hospitalization. There was a strong
edictor of the primary end point (odds ratio 1.12, 95% confidence interval
in the LGE group divided into high and low LGE (division point 4.8%
outcome for the primary end point between the 2 subgroups. LGE 
dolinium enhancement.late en
ractio
ant pr
ientscenario resulting in fibrosis. Exposure to pathogens such as
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November 21, 2006:1977–85 Prognosis in DCM by CMRiruses triggers fibrosis. Early CMR imaging of patients
ith acute myocarditis shows characteristic epicardial or
idwall late enhancement in the acute phase (15), which
ay persist in the subset of patients in whom DCM
ubsequently develops. Histopathological studies of hearts
rom patients with myocarditis confirm fibrosis and inflam-
atory exudates (30). However, other histopathological
tudies of patients with end-stage DCM do show interstitial
brosis in the absence of any histological features of
nflammation, suggesting that fibrosis may exist in the
bsence of myocarditis (21). Previous studies have implicated
yocarditis as the cause of fibrosis in 10% of cases (31), and we
ould speculate that a proportion of patients in our study with
CM, including those with fibrosis, may have had a myocar-
itis at some time with subsequent development to DCM.
The occurrence of sustained monomorphic VT is linked
o a scar-related re-entrant mechanism similar to that of
AD. The arrhythmia is uniformly inducible and is often
efractory to pharmacological therapy. In animal studies and
retransplantation heart assessments, sustained VT is asso-
iated with more extensive myocardial fibrosis and nonuni-
orm anisotropy, involving both the endocardium and epi-
ardium, compared with those without sustained re-entry
32,33). Myocardial fibrosis is also associated with adverse
entricular remodeling leading to the development of heart
ailure in animal and human studies (26,27).
Although previous invasive studies in DCM patients have
hown myocardial fibrosis, these studies have relied on
issue biopsy, which may miss affected areas, resulting in a
igh sampling error; CMR is able to detect replacement
brosis in cardiomyopathy caused by both ischemic and
onischemic causes (13,35–37). In ischemic heart disease,
etection of fibrosis is useful in viability assessment (12),
nd recent work has shown that infarct size characterized by
MR is a better identifier of patients with substrate for
ustained VT than LV EF (10). Our study using CMR to
etect myocardial fibrosis accords with studies in other
onditions. Recently published data have also shown that
brosis as detected by LGE-CMR is significantly predictive
f inducible VT in DCM, even after adjustment for LV EF
n a multivariate model (38). In arrhythmogenic RV car-
iomyopathy, RV myocardial fibrosis detected by CMR had
n excellent correlation with histopathology and predicted
nducible VT (37). However, there is controversy over the
ositive predictive accuracy of inducibility of VT alone in
onsecutive series of patients (39).
Patients with fibrosis also have a higher incidence of
ospitalizations. This may be the result of several mecha-
isms. Fibrosis may predispose to arrhythmia, and paroxys-
al tachycardia can result in heart failure decompensation
40). The presence of fibrosis may also render the ventricle
ess compliant, thereby impairing diastolic function with
ncreasing filling pressures and producing a restrictive filling
attern (41). This may also precipitate pulmonary edema or
trial tachycardias, resulting in decompensation, necessitat-
ng hospital admission. To date, there have been few gutcome data reflecting the prognostic implications of
dentifying myocardial fibrosis in vivo.
In our study, the presence of fibrosis predicted a poorer
utcome of the primary end point in patients with DCM.
ur data imply that patients with DCM and fibrosis may
enefit from early and more aggressive treatment of their
V dysfunction with currently available pharmacotherapy
nd mechanical resynchronization treatment. In addition,
ur study showed a significantly higher rate of SCD/VT in
atients with midwall fibrosis even after adjustment for
VEF. However, because of the low number of events in
he cohort, this finding should be interpreted with caution.
e propose that CMR could therefore potentially play an
mportant role in early stratification of treatment in patients
ith DCM. Our findings also emphasize the pressing need
or larger studies to further evaluate the possible incidence
f higher arrhythmic episodes in patients with midwall
brosis, because these have important clinical implications
or risk stratification of patients requiring implantable
ardioverter-defibrillators.
tudy limitations. The LGE patients were significantly
ounger than the LGE patients. The importance of this
eems limited because multivariate analysis using age did
ot alter the findings. Potentially this may reflect a different
tiology, although there was no evidence for this. LGE
atients also had more adverse LV remodeling at baseline.
y multivariate analysis, however, LGE was a better marker
f outcome than LVESV, LVEDV, LVEF, or RVEF. This
nding supports earlier work showing that in ischemic heart
isease, the presence of fibrosis is a better marker of VT
nducibility than LVEF (10). None of the patients under-
ent myocardial biopsy for the diagnosis of DCM, as is
ormal in our center and per guidelines (42). The diagnosis
f DCM was based on clinical history and examination
oupled with findings from echocardiography and normal
ndings at coronary angiography. It was not considered
thical to put forward patients for biopsy because this
nvestigation is associated with significant clinical risk and is
ubject to sampling error (34,43). At baseline, there was a
ignificant difference between groups in use of digoxin.
here are, however, no prognostic data to indicate that this
ould make a difference in the primary end point in DCM
44). By contrast, overall use of beta-blockers and
ngiotensin-converting enzyme inhibitors/angiotensin re-
eptor blockers was similar between groups, with a high
sage rate comparable with that of SCD-HEFT (Sudden
ardiac Death in Heart Failure Trial). Another limitation is
he assessment of VT. Not all patients had regular investi-
ations for arrhythmia monitoring. A “real-life” approach
as used, in which referring physicians investigated for the
resence of arrhythmias as was clinically indicated. There is
o evidence of bias between groups because the proportion
f patients receiving Holter monitors was not significantly
ifferent (47% in LGE group vs. 46% in the LGE
roup, p  0.90).
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Prognosis in DCM by CMR November 21, 2006:1977–85onclusions. This is the first study to evaluate the prog-
ostic significance of detecting myocardial fibrosis in DCM.
atients with myocardial fibrosis had a higher incidence of
he combined primary end point of all-cause mortality and
ospitalization, and this finding persisted after correction
or baseline patient differences in LV/RV volumes/function,
ge, and treatment with digoxin. Patients with fibrosis also
ad a higher incidence of SCD/VT. These findings have
otentially important implications for the risk stratification
f DCM patients and may have application for refinement
f patient groups suitable for device therapy.
cknowledgments
e thank Juanra Gimeno for assistance in setting up the
atient database and Jane McCrohon for assistance. We also
hank all of the participating cardiologists and general
ractitioners who contributed patients to the project and
ho assisted with the clinical follow-up.
eprint requests and correspondence: Dr. Dudley Pennell,
ardiovascular Magnetic Resonance Unit, Royal Brompton
ospital, Sydney Street, London SW3 6NP, United Kingdom.
-mail: d.pennell@imperial.ac.uk.
EFERENCES
1. Adams KF, Dunlap SH, Sueta CA, et al. Relation between gender,
etiology and survival in patients with symptomatic heart failure. J Am
Coll Cardiol 1996;28:1781–8.
2. Cleland JG, Daubert JC, Erdmann E, et al.; Cardiac Resynchronization-
Heart Failure (CARE-HF) Study Investigators. The effect of cardiac
resynchronization on morbidity and mortality in heart failure. N Engl
J Med 2005;352:1539–49.
3. Bristow MR, Saxon LA, Boehmer J, et al.; Comparison of Medical
Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION)
Investigators. The effect of cardiac resynchronization on morbidity and
mortality in heart failure. N Engl J Med 2004;350:2140–50.
4. Kadish A, Dyer A, Daubert JP, et al.; Defibrillators in Non-Ischemic
Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators.
Prophylactic defibrillator implantation in patients with nonischemic
dilated cardiomyopathy. N Engl J Med 2004;350:2151–8.
5. Bardy GH, Lee KL, Mark DB, et al.; Sudden Cardiac Death in Heart
Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implant-
able cardioverter-defibrillator for congestive heart failure. N Engl
J Med 2005;352:225–37.
6. Nichol G, Kaul P, Huszti E, Bridges JF. Cost-effectiveness of cardiac
resynchronization therapy in patients with symptomatic heart failure.
Ann Intern Med 2004;141:343–51.
7. Gradaus R, Block M, Brachmann J, et al.; German EURID Registry.
Mortality, morbidity, and complications in 3344 patients with im-
plantable cardioverter defibrillators: results from the German ICD
Registry EURID. Pacing Clin Electrophysiol 2003;26:1511–8.
8. Abraham WT, Fisher WG, Smith AL, et al.; MIRACLE Study
Group. Multicenter InSync Randomized Clinical Evaluation. N Engl
J Med 2002;346:1845–53.
9. Nanthakumar K, Epstein AE, Kay GN, Plumb VJ, Lee DS. Prophy-
lactic implantable cardioverter-defibrillator therapy in patients with
left ventricular systolic dysfunction: a pooled analysis of 10 primary
prevention trials. J Am Coll Cardiol 2004;44:2166–72.
0. Bello D, Fieno DS, Kim RJ, et al. Infarct morphology identifies
patients with substrate for sustained ventricular tachycardia. J Am Coll
Cardiol 2005;45:1104–8.
1. Bello D, Shah DJ, Farah GM, et al. Gadolinium cardiovascular
magnetic resonance predicts reversible myocardial dysfunction and
remodeling in patients with heart failure undergoing beta-blocker
therapy. Circulation 2003;108:1945–53.2. Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced
magnetic resonance imaging to identify reversible myocardial dysfunc-
tion. N Engl J Med 2000;343:1445–53.
3. McCrohon JA, Moon JC, Prasad SK, et al. Differentiation of heart
failure related to dilated cardiomyopathy and coronary artery disease
using gadolinium-enhanced cardiovascular magnetic resonance. Cir-
culation 2003;108:54–9.
4. Richardson P, McKenna W, Bristow M, et al. Report of the 1995
World Health Organization/International Society and Federation of
Cardiology Task Force on the Definition and Classification of Car-
diomyopathies. Circulation 1996;93:841–2.
5. Mahrholdt H, Goedecke C, Wagner A, et al. Cardiovascular magnetic
resonance assessment of human myocarditis: a comparison to histology
and molecular pathology. Circulation 2004;109:1250–8.
6. Grothues F, Smith GC, Moon JC, et al. Comparison of interstudy
reproducibility of cardiovascular magnetic resonance with two-
dimensional echocardiography in normal subjects and in patients with
heart failure or left ventricular hypertrophy. Am J Cardiol 2002;90:
29–34.
7. Epstein AE, Carlson MD, Fogoros RN, Higgins SL, Venditti FJ Jr.
Classification of death in antiarrhythmia trials. J Am Coll Cardiol
1996;27:433–42.
8. Torp-Pedersen C, Poole-Wilson PA, Swedberg K, et al.; COMET
Investigators. Effects of metoprolol and carvedilol on cause-specific
mortality and morbidity in patients with chronic heart failure—
COMET. Am Heart J 2005;149:370–6.
9. The SOLVD Investigators. Effect of enalapril on mortality and the
development of heart failure in asymptomatic patients with reduced
left ventricular ejection fractions. N Engl J Med 1992;327:685–91.
0. LaVecchia L, Paccanaro M, Bonanno C, Varotto L, Ometto R,
Vincenzi M. Left ventricular versus biventricular dysfunction in
idiopathic dilated cardiomyopathy. Am J Cardiol 1999;83:120–2.
1. de Leeuw N, Ruiter DJ, Balk AH. Histopathologic findings in
explanted heart tissue from patients with end-stage idiopathic dilated
cardiomyopathy. Transpl Int 2001;14:299–306.
2. Hughes SE, McKenna WJ. New insights into the pathology of
inherited cardiomyopathy. Heart 2005;91:257–64.
3. O’Neill JO, McCarthy PM, Brunken RC, et al. PET abnormalities in
patients with nonischemic cardiomyopathy. J Card Fail 2004;10:
244–9.
4. Knaapen P, Boellaard R, Gotte MJ, et al. Perfusable tissue index as a
potential marker of fibrosis in patients with idiopathic dilated cardio-
myopathy. J Nucl Med 2004;45:1299–304.
5. Ferrari P, Bianchi G. The genomics of cardiovascular disorders:
therapeutic implications. Drugs 2000;59:1025–42.
6. Ryoke T, Gu Y, Mao L, et al. Progressive cardiac dysfunction and
fibrosis in the cardiomyopathic hamster and effects of growth hormone
and angiotensin-converting enzyme inhibition. Circulation 1999;100:
1734–43.
7. Heling A, Zimmermann R, Kostin S, et al. Increased expression of
cytoskeletal, linkage, and extracellular proteins in failing human
myocardium. Circ Res 2000;86:846–53.
8. Izawa H, Murohara T, Nagata K, et al. Mineralocorticoid receptor
antagonism ameliorates left ventricular diastolic dysfunction and myo-
cardial fibrosis in mildly symptomatic patients with idiopathic dilated
cardiomyopathy: a pilot study. Circulation 2005;112:2940–5.
9. Varghese A, Pennell DJ. Late gadolinium enhanced cardiovascular
magnetic resonance in Becker muscular dystrophy. Heart 2004;90:e59.
0. Artez HT, Billingham ME, Edwards WD, et al. Myocarditis: a
histopathological definition and classification. Am J Cardiovasc Pathol
1987;1;3–14.
1. Felker GM, Thompson RE, Hare JM, et al. Underlying causes and
long-term survival in patients with initially unexplained cardiomyop-
athy. N Engl J Med 2000;342:1077–84.
2. Brandenburg RO. Cardiomyopathies and their role in sudden death.
J Am Coll Cardiol 1985;5 Suppl:185–9B.
3. Hsia HH, Marchlinski FE. Electrophysiology studies in patients with
dilated cardiomyopathies. Card Electrophysiol Rev 2002;6:472–81.
4. Kubo N, Morimoto S, Hiramitsu S, et al. Feasibility of diagnosing
chronic myocarditis by endomyocardial biopsy. Heart Vessels 1997;12:
167–70.
5. Wu E, Judd RM, Vargas JD. Visualisation of presence, location, and
transmural extent of healed Q-wave and nonQ-wave myocardial
infarction. Lancet 2001;357:21–8.
33
3
3
4
4
4
4
4
1985JACC Vol. 48, No. 10, 2006 Assomull et al.
November 21, 2006:1977–85 Prognosis in DCM by CMR6. Moon JC, McKenna WJ, McCrohon JA, Elliott PM, Smith GC,
Pennell DJ. Toward clinical risk assessment in hypertrophic cardio-
myopathy with gadolinium cardiovascular magnetic resonance. J Am
Coll Cardiol 2003;41:1561–7.
7. Tandri H, Saranathan M, Rodriguez ER, et al. Noninvasive detection
of myocardial fibrosis in arrhythmogenic right ventricular cardiomy-
opathy using delayed-enhancement magnetic resonance imaging. J Am
Coll Cardiol 2005;45:98–103.
8. Nazarian S, Bluemke DA, Lardo AC, et al. Magnetic resonance
assessment of the substrate for inducible ventricular tachycardia in
nonischemic cardiomyopathy. Circulation 2005;112:2821–5.
9. Huikuri HV, Makikallio TH, Raatikainen MJ, Perkiomaki J, Castel-
lanos A, Myerburg RJ. Prediction of sudden cardiac death: appraisal of
the studies and methods assessing the risk of sudden arrhythmic death.
Circulation 2003;108:110–5.
0. Melenovsky V, Hay I, Fetics BJ, et al. Functional impact of rate
irregularity in patients with heart failure and atrial fibrillation receiving
cardiac resynchronization therapy. Eur Heart J 2005;26:705–11.1. MacKenna DA, Omens JH, MuCulloch AD, Covell JW. Contribu-
tion of collagen matrix to passive left ventricular mechanics in isolated
rat hearts. Am J Physiol 1994;266:H1007–18.
2. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005
guideline update for the diagnosis and management of chronic
heart failure in the adult: a report of the American College of
Cardiology/American Heart Association Task Force on Practice
Guidelines (Writing Committee to Update the 2001 Guidelines for
the Evaluation and Management of Heart Failure). J Am Coll
Cardiol 2005;46:e1– 82.
3. Deckers JW, Hare JM, Baughman KL. Complications of trans-
venous right ventricular endomyocardial biopsy in adult patients
with cardiomyopathy: a seven-year survey of 546 consecutive
diagnostic procedures in a tertiary referral center. J Am Coll
Cardiol 1992;19:43–7.
4. The Digitalis Investigation Group. The effect of digoxin on mortality
and morbidity in patients with heart failure. N Engl J Med 1997;
336:525–33.
